NASDAQ: DAWN

Day One Biopharmaceuticals Inc Stock Forecast, Predictions & Price Target

The consensus among 5 Wall Street analysts covering (NASDAQ: DAWN) stock is to Strong Buy DAWN stock.

Out of 5 analysts, 3 (60%) are recommending DAWN as a Strong Buy, 2 (40%) are recommending DAWN as a Buy, 0 (0%) are recommending DAWN as a Hold, 0 (0%) are recommending DAWN as a Sell, and 0 (0%) are recommending DAWN as a Strong Sell.

If you're new to stock investing, here's how to buy Day One Biopharmaceuticals stock.

(NASDAQ: DAWN) Day One Biopharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.

Day One Biopharmaceuticals's revenue in 2024 is $0.On average, 6 Wall Street analysts forecast DAWN's revenue for 2024 to be $1,471,470,446, with the lowest DAWN revenue forecast at $505,113,385, and the highest DAWN revenue forecast at $1,861,403,997. On average, 6 Wall Street analysts forecast DAWN's revenue for 2025 to be $7,810,468,648, with the lowest DAWN revenue forecast at $2,243,297,681, and the highest DAWN revenue forecast at $11,817,730,633.

In 2026, DAWN is forecast to generate $17,756,745,450 in revenue, with the lowest revenue forecast at $6,447,623,797 and the highest revenue forecast at $25,447,053,042.

According to 5 Wall Street analysts that have issued a 1 year DAWN price target, the average DAWN price target is $38.60, with the highest DAWN stock price forecast at $44.00 and the lowest DAWN stock price forecast at $33.00.

On average, Wall Street analysts predict that Day One Biopharmaceuticals's share price could reach $38.60 by May 7, 2025. The average Day One Biopharmaceuticals stock price prediction forecasts a potential upside of 190.88% from the current DAWN share price of $13.27.

(NASDAQ: DAWN) forecast ROE is N/A, which is considered weak.